Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 143
- Markets & Stocks
European Cannabis Stocks Review: MGC Pharma’s Shares Jump Nearly 50% After Long Covid Study, Love Hemp Re-shuffles Boardroom After Months Of Suspension, & More From Akanda
FOLLOWING weeks of widespread losses throughout the European cannabis sector in the wake of ongoing macroeconomic headwinds, this week saw a number of prominent players secure double-digit share price rises.
- Opinion
Having A Fair, Reciprocal Relationship With Patients ‘Isn’t Just The Right Thing To Do, It Simply Makes Business Sense’
Mary Biles, author of The CBD Book and host of the podcast ‘Cannabis Voices’, asks whether for all the rhetoric around patient engagement across the cannabis industry, the message has really sunk in.
- CBD Market
Cellular Goods Launches New Marketing Drive As It Leads Charge Against CBD’s ‘Unfair’ Online Advertising Blockade
CELLULAR Goods, alongside a coalition of other CBD brands, is leading the charge against rules put in place by the world’s leading big tech companies which all but ban CBD companies from advertising online.
- Data & Analysis
New Data Reveals England’s Private Medical Cannabis Prescriptions In 2021 Were More Than 9 Times That Of 2020
FOLLOWING last week’s dramatic political developments in the UK, which saw nearly 50 Members of Parliament quit in 48 hours, the prospect of making medical cannabis more affordable and accessible for the UK’s estimated 1.4m patients has inevitably fallen further down the list of political priorities.
- News
Italy Could Allow Home Cultivation Of Up To 4 Cannabis Plants By The End Of The Year
ITALY has become the latest European country to explore significant cannabis liberalisation, coming just weeks after similar developments in Spain.
- Adult-Use
European Cannabis Stocks Review: Kanabo Climbs 25% Following Spanish Medical Legalisation Announcement, DeepVerge Continues Run Of Success
AS Democrats condemn President Joe Biden’s almost complete lack of action on promises to enact cannabis reform at the federal level, progress across the rest of the world has continued at pace this week.
- Adult-Use
ICBC Berlin 2022 Set To Be Biggest Yet As It Prepares To Become Epicentre Of German Adult-Use Cannabis Conversation
Last week, German ministers held the last of four separate expert hearings, featuring 200 experts from various disciplines, on how its upcoming adult-use cannabis market should be rolled out.
- Uncategorized
ICBC Berlin 2022 wird die bisher größte Veranstaltung und bereitet sich darauf vor, das Epizentrum der deutschen Cannabis-Konversation für Erwachsene zu werden
Letzte Woche haben die deutschen Minister die letzte von vier separaten Expertenanhörungen abgehalten, an denen 200 Experten verschiedener Fachrichtungen teilnahmen, um zu erörtern, wie der kommende Cannabismarkt für Erwachsene eingeführt werden soll.
- News
GrowLab Organics Receives First Export Licence On The Isle Of Man Amid String Of Measures To Bolster Island’s Cannabis Industry
THE Isle of Man has become the latest British crown dependency to bolster its burgeoning cannabis industry after issuing its first licence for medical cannabis export last week.
- CBD Market
European CBD Applications Will Require ‘Complicated And Huge’ Human Studies, Admit EFSA
FOLLOWING the European Food Safety Authority’s (EFSA) controversial decision to ‘stop the clock’ on all CBD novel food applications last month, the regulator addressed the industry in a virtual public forum last week.
- Medical
Overseed Becomes First Company To Cultivate Medical Cannabis In France
As reported by NewsWeed SIX months after obtaining ANSM (French Agency for the Safety of Health products) approval and raising €2.5 million, Overseed is launching a new research and development program in the cultivation of medical cannabis.
- Pharmaceutical
European Cannabis Stocks Review: Jazz Pharmaceuticals Fails Phase 3 Trail For Sativex, CiiTech Pushes Ahead With IPO Plans
Jazz Pharmaceuticals Jazz Pharmaceuticals, which has become the world’s largest exporter of medical cannabis products since it bought GW Pharmaceuticals for $7.2bn last year, saw its stock price rise this week despite news that its flagship product failed phase 3 trials.











